Uncovering the antimalarial potential of toad venoms through a bioassay-guided fractionation process. (December 2022)

• Record Type: Journal Article
• Authors: Wells, Mathilde; Fossépré, Mathieu; Hambye, Stéphanie; Surin, Mathieu; Blankert, Bertrand
• Is Part Of: International journal for parasitology. Volume 20(2022)
• Page Start: 97
• Page End: 107
• Publication Date: 2022-12
• Subjects: Malaria -- Rhinella marina -- Bufadienolide -- Toad venom -- Separative techniques; Parasitic diseases -- Chemotherapy -- Periodicals; Drug resistance -- Periodicals; 616.96061
• DOI: 10.1016/j.ijpddr.2022.10.001
• Languages: English
• ISSNs: 2211-3207

Abstract

Abstract: Malaria remains to date one of the most devastating parasitic diseases worldwide. The fight against this disease is rendered more difficult by the emergence and spread of drug-resistant strains. The need for new therapeutic candidates is now greater than ever. In this study, we investigated the antiplasmodial potential of toad venoms. The wide array of bioactive compounds present in Bufonidae venoms has allowed researchers to consider many potential therapeutic applications, especially for cancers and infectious diseases. We focused on small molecules, namely bufadienolides, found in the venom of Rhinella marina (L.) . The developed bio-guided fractionation process includes a four solvent-system extraction followed by fractionation using flash chromatography. Sub-fractions were obtained through preparative TLC. All samples were characterized using chromatographic and spectrometric techniques and then underwent testing on in vitro Plasmodium falciparum cultures. Two strains were considered: 3D7 (chloroquine-sensitive) and W2 (chloroquine-resistant). This strategy highlighted a promising activity for one compound named resibufogenin. With IC50 values of (29 ± 8) μg/mL and (23 ± 1) μg/mL for 3D7 and W2 respectively, this makes it an interesting candidate for further investigation. A molecular modelling approach proposed a potential binding mode of resibufogenin to Plasmodium falciparum adenine-triphosphate 4 pump as antimalarial drug target. Graphical abstract: Image 1